Stock Traders Purchase High Volume of Call Options on Genmab A/S (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the target of some unusual options trading activity on Thursday. Traders bought 24,213 call options on the company. This is an increase of approximately 485% compared to the average volume of 4,137 call options.

Wall Street Analysts Forecast Growth

GMAB has been the subject of several research reports. New Street Research set a $43.00 price target on shares of Genmab A/S in a research report on Wednesday, July 22nd. Truist Financial reissued a “buy” rating and set a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a report on Thursday, October 29th. HC Wainwright lifted their price objective on shares of Genmab A/S from $50.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Guggenheim boosted their price objective on shares of Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, JPMorgan Chase & Co. upgraded Genmab A/S from a “neutral” rating to an “overweight” rating in a report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Genmab A/S has an average rating of “Buy” and a consensus target price of $53.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GMAB. WINTON GROUP Ltd increased its position in shares of Genmab A/S by 158.9% in the second quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock valued at $1,124,000 after buying an additional 25,100 shares in the last quarter. Diversify Wealth Management LLC purchased a new position in shares of Genmab A/S during the 1st quarter valued at approximately $1,216,000. SummitTX Capital L.P. purchased a new position in shares of Genmab A/S during the 1st quarter valued at approximately $2,263,000. Legacy Wealth Asset Management LLC grew its stake in Genmab A/S by 164.1% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after acquiring an additional 63,484 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after acquiring an additional 921,700 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of GMAB stock opened at $51.37 on Friday. The stock’s 50-day moving average is $41.15 and its 200 day moving average is $31.60. Genmab A/S has a 1-year low of $23.62 and a 1-year high of $59.97. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.45 and a quick ratio of 2.43. The company has a market cap of $32.06 billion, a P/E ratio of 39.80, a PEG ratio of 2.08 and a beta of 0.73.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.20 billion. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. Research analysts predict that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.